Maninil

Glibenclamide, the active ingredient in Maninil, is a sulfonylurea presented as an oral tablet for oral use. It stimulates insulin release from pancreatic beta cells, thereby helping to lower elevated blood glucose levels in adults diagnosed with type 2 diabetes mellitus.

GNH USA supplies Maninil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Maninil, a sulfonylurea antidiabetic agent, is employed to improve glycaemic control in conditions related to insulin deficiency or resistance.

- Type 2 diabetes mellitus: improves overall blood glucose regulation. - Inadequate response to diet and exercise in adults: provides additional glucose‑lowering effect. - Need for oral antidiabetic therapy: serves as a sulfonylurea option when insulin is not yet required.

Maninil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypoglycaemia: feeling of weakness, sweating, or dizziness due to low blood sugar. - Weight gain: modest increase in body weight with chronic use. - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe hypoglycaemia: confusion, loss of consciousness, or seizures. - Allergic reactions: rash, pruritus, or angio‑edema. - Blood dyscrasias: neutropenia or agranulocytosis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Maninil, several safety considerations should be observed.

- Blood glucose monitoring: regularly check levels to avoid hypoglycaemia. - Renal impairment: dose may need adjustment or avoidance in severe dysfunction. - Hepatic disease: use with caution and monitor liver function. - Sulfonylurea hypersensitivity: discontinue if allergic signs appear. - Concomitant medications: review for agents that may potentiate or diminish glucose‑lowering effects. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Maninil can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concurrent insulin or other sulfonylureas: risk of severe hypoglycaemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may increase glibenclamide plasma concentrations. - MAO‑A inhibitors: can potentiate hypoglycaemic episodes.

Moderate Interactions (Monitor Closely): - CYP2C9 inducers (e.g., rifampicin, carbamazepine): may reduce drug effectiveness. - NSAIDs (e.g., ibuprofen, naproxen): can enhance hypoglycaemic risk. - Thiazide diuretics: may augment glucose‑lowering effect. - Beta‑blockers: can mask hypoglycaemia symptoms.